Sage Therapeutics Stock Soars

Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial instability. Learn more on SAGE stock here.
Biogen Wants to Buy Its Partner Sage for Almost No Premium
Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01. Sage’s board will now review and evaluate the offer,
Biogen proposes acquisition of partner Sage Therapeutics
The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.
1SAGE, BIIB : Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy:...
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.
BofA moves to No Rating on Sage Therapeutics after Biogen bid
BofA is moving to No Rating on Sage Therapeutics (SAGE) after the company announced it has received an unsolicited, nonbinding acquisition
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
Key Takeaways Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will review the offer.
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
BioPharma Dive4d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
FiercePharma5d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
BioSpace4d
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...
pharmaphorum5d
Biogen offers to buy out wilting Sage for $442 million
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...
BioPharma Dive2d
At JPM, Biogen CEO tries to take down the deal temperature
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...